I 
116TH CONGRESS 
2D SESSION 
H. R. 6482 
To require the Secretary of Health and Human Services to maintain a 
list of the country of origin of all drugs marketed in the United States, 
to ban the use of Federal funds for the purchase of drugs manufactured 
in China, and for other purposes. 
IN THE HOUSE OF REPRESENTATIVES 
APRIL 10, 2020 
Mr. GALLAGHER (for himself, Ms. CHENEY, Ms. STEFANIK, and Mr. BUDD) 
introduced the following bill; which was referred to the Committee on En-
ergy and Commerce, and in addition to the Committees on Ways and 
Means, Armed Services, and Veterans’ Affairs, for a period to be subse-
quently determined by the Speaker, in each case for consideration of such 
provisions as fall within the jurisdiction of the committee concerned 
A BILL 
To require the Secretary of Health and Human Services 
to maintain a list of the country of origin of all drugs 
marketed in the United States, to ban the use of Federal 
funds for the purchase of drugs manufactured in China, 
and for other purposes. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Protecting Our Phar-
maceutical Supply Chain from China Act of 2020’’. 
VerDate Sep 11 2014 
03:53 Apr 18, 2020
Jkt 099200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H6482.IH
H6482
kjohnson on DSK79L0C42PROD with BILLS
SEC. 2. COUNTRY OF ORIGIN OF DRUGS. 
(a) IN GENERAL.—Subchapter A of chapter V of the 
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 351 
et seq.) is amended by adding at the end the following: 
‘‘SEC. 524B. REGISTRY OF DRUGS PRODUCED OUTSIDE THE 
UNITED STATES. 
‘‘(a) IN GENERAL.—The Secretary shall compile and 
maintain a list of all drugs approved under subsection (c) 
or (j) of section 505 of this Act or licensed under sub-
section (a) or (k) of section 351 of the Public Health Serv-
ice Act, and any active ingredients in such drugs, that— 
‘‘(1) are manufactured outside of the United 
States; and 
‘‘(2) are determined by the Secretary to be crit-
ical to the health and safety of consumers in the 
United States. 
‘‘(b) ADDITIONAL LIST.—In conjunction with the list 
described in subsection (a), the Secretary shall compile 
and maintain a list of drugs included on such list that 
are exclusively produced in, or use active or inactive ingre-
dients produced in, the People’s Republic of China. 
‘‘(c) REQUIREMENT.—The list described in sub-
section (a) shall, with respect to each drug included on 
the list, provide information about the drug’s supply chain, 
including each step in the supply chain that occurs prior 
to the drug’s importation into the United States.’’. 
VerDate Sep 11 2014 
03:53 Apr 18, 2020
Jkt 099200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H6482.IH
H6482
kjohnson on DSK79L0C42PROD with BILLS
(b) FEDERAL HEALTH PROGRAM PURCHASE
OF 
DRUGS.— 
(1) IN GENERAL.—Notwithstanding any other 
provision of law, the Department of Health and 
Human Services, the Department of Veterans Af-
fairs, the Department of Defense, and any other 
Federal health care program (as defined in section 
1128B(f) of the Social Security Act (42 U.S.C. 
1320a–7b(b)), with respect to the purchase of a 
drug by such agency or program, the following shall 
apply: 
(A) By 2022, a purchaser of drugs de-
scribed in this subsection shall only purchase 
drugs that contain 60 percent or more of their 
active pharmaceutical ingredients manufactured 
in countries— 
(i) other than the People’s Republic of 
China; and 
(ii) that meet the Food and Drug Ad-
ministration’s health and safety standards. 
(B) By 2023, a purchaser of drugs de-
scribed in this subsection shall only purchase 
drugs that contain 100 percent of their active 
pharmaceutical ingredients manufactured in 
countries— 
VerDate Sep 11 2014 
03:53 Apr 18, 2020
Jkt 099200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H6482.IH
H6482
kjohnson on DSK79L0C42PROD with BILLS
(i) other than the People’s Republic of 
China; and 
(ii) that meet the Food and Drug Ad-
ministration’s health and safety standards. 
(2) WAIVERS.—The Secretary of Health and 
Human Services may issue waivers of the require-
ments under paragraph (1) for any agency or pro-
gram that is unable to meet such requirements and 
demonstrates a need for the waiver. No waiver may 
be issued under this paragraph for drugs that are 
purchased on or after January 1, 2025. 
(c) LABELING REQUIREMENT.—Section 502 of the 
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 352) 
is amended by adding at the end the following: 
‘‘(ee) If it is a drug and its labeling does not specify 
the country of origin of each active ingredient contained 
in the drug.’’. 
SEC. 3. TEMPORARY 100 PERCENT EXPENSING FOR PHAR-
MACEUTICAL AND MEDICAL DEVICE MANU-
FACTURING PROPERTY. 
(a) IN GENERAL.—For purposes of section 168(k) of 
the Internal Revenue Code of 1986, in the case of any 
qualified pharmaceutical and medical device manufac-
turing property which is placed in service after December 
31, 2019, and before January 1, 2026— 
VerDate Sep 11 2014 
03:53 Apr 18, 2020
Jkt 099200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H6482.IH
H6482
kjohnson on DSK79L0C42PROD with BILLS
(1) such property shall be treated as qualified 
property (within the meaning of such section); 
(2) the applicable percentage otherwise deter-
mined under section 168(k)(6) of such Code with re-
spect to such property shall be 100 percent; and 
(3) paragraph (8) of such section shall not 
apply. 
(b) QUALIFIED PHARMACEUTICAL
AND MEDICAL 
DEVICE MANUFACTURING PROPERTY.—For purposes of 
this section, the term ‘‘qualified pharmaceutical and med-
ical device manufacturing property’’ means any tangible 
property placed in service in the United States as part 
of the construction or expansion of property for the manu-
facture of drugs (as defined in section 201(g) of the Fed-
eral Food, Drug, and Cosmetic Act (21 U.S.C. 321(g)) 
or medical devices (as defined in section 201(h) of such 
Act (21 U.S.C. 321(h)). 
(c) TERMINATION.—This section shall not apply to 
any property placed in service after December 31, 2025. 
SEC. 4. RULE OF CONSTRUCTION. 
Nothing in this Act shall be construed to divert the 
resources of the Food and Drug Administration from re-
sponding to the COVID-19 public health emergency. 
Æ 
VerDate Sep 11 2014 
03:53 Apr 18, 2020
Jkt 099200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6301
E:\BILLS\H6482.IH
H6482
kjohnson on DSK79L0C42PROD with BILLS